文献速递浆细胞疾病

BH3模拟物工具包指导骨髓瘤治疗中BCL2与MCL1 BH3模拟物的分别使用

BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment.
PubMed 文献 · Blood · 2018-10-11

研究用BH3模拟物工具包分析60例患者恶性浆细胞对BCL2、BCLXL或MCL1的依赖,发现BCL2依赖多见于CCND1亚组(83%),MCL1依赖从诊断时33%升至复发时69%,35%样本存在共依赖,部分患者无BH3模拟物靶向,BAK对A1210477诱导细胞死亡关键,BCLXL参与A1210477耐药。

要点

  • 全队列BCL2依赖主要见于CCND1亚组(83%)。
  • MCL1依赖从诊断时33%显著增至复发时69%。
  • 35%患者样本存在BCL2/MCL1或BCLXL/MCL1共依赖。

核心结论

  • 研究为在骨髓瘤诊断和复发时合理使用维奈克拉和/或MCL1 BH3模拟物进行临床评估开辟了道路。

研究设计与样本

  • 使用BH3模拟物工具包研究60例患者恶性浆细胞对BCL2、BCLXL或MCL1的依赖,采用无偏BH3模拟物细胞死亡k-means聚类分析依赖性。

主要发现

  • 全队列中BCL2依赖主要见于CCND1亚组(83%)。
  • MCL1依赖从诊断时33%显著增至复发时69%。
  • 35%患者样本显示BCL2/MCL1或BCLXL/MCL1共依赖。
  • 鉴定出一组不被任何BH3模拟物靶向的患者,主要见于诊断时且不携带常见重现性易位的患者。
  • BAK敲低可保护细胞死亡,且A1210477处理可完全且早期破坏MCL1/BAK复合物,表明BAK对MCL1模拟物A1210477诱导的细胞死亡至关重要。

临床怎么用

  • 作者认为研究为在骨髓瘤诊断和复发时合理使用维奈克拉和/或MCL1 BH3模拟物进行临床评估开辟了道路。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BH3 mimetics are promising drugs for hematologic malignancies that trigger cell death by promoting the release of proapoptotic BCL2 family members from antiapoptotic proteins. Multiple myeloma is considered to be a disease dependent mainly on MCL1 for survival, based mostly on studies using cell lines. We used a BH3-mimetic toolkit to study the dependency on BCL2, BCLXL, or MCL1 in malignant plasma cells from 60 patients. Dependencies were analyzed using an unbiased BH3 mimetics cell-death clustering by k-means. In the whole cohort of patients, BCL2 dependency was mostly found in the CCND1 subgroup (83%). Of note, MCL1 dependence significantly increased from 33% at diagnosis to 69% at relapse, suggesting a plasticity of the cellular dependency favoring MCL1 dependencies at relapse. In addition, 35% of overall patient samples showed codependencies on either BCL2/MCL1 or BCLXL/MCL1. Finally, we identified a group of patients not targeted by any of the BH3 mimetics, predominantly at diagnosis in patients not presenting the common recurrent translocations. Mechanistically, we demonstrated that BAK is crucial for cell death induced by MCL1 mimetic A1210477, according to the protection from cell death observed by BAK knock-down, as well as the complete and early disruption of MCL1/BAK complexes on A1210477 treatment. Interestingly, this complex was also dissociated in A1210477-resistant cells, but free BAK was simultaneously recaptured by BCLXL, supporting the role of BCLXL in A1210477 resistance. In conclusion, our study opens the way to rationally use venetoclax and/or MCL1 BH3 mimetics for clinical evaluation in myeloma at both diagnosis and relapse.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Gomez-Bougie P, Maiga S, Tessoulin B, et al. BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment. Blood. 2018. PMID: 30309889. doi:10.1182/blood-2018-03-836718

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。